FDA says it is reprioritizing planned inspections for the rest of the year due to challenges it faces after 170 administrative and management staff were cut 4/1 under HHS’s mass firings.
Former FDA commissioner Mark McClellan says it will be a challenge for the agency to come through the massive reorganization and staff reduction that is underway and be able to do more with less.
FDA says it is reprioritizing planned inspections for the rest of the year due to challenges it faces after 170 administrative and management staff were cut 4/1 under HHS’s mass firings.
Former FDA commissioner Mark McClellan says it will be a challenge for the agency to come through the massive reorganization and staff reduction that is underway and be able to do more with less.
FDA misses its 4/1 user fee review action target date on a Novavax BLA seeking full approval for its current Covid-19 vaccine.
Industry associations sound alarms and frustrations as they weigh how FDA staff cuts will impact product development, FDA reviews and approvals.
